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Abstract
Malignancy in cancer is associated with aerobic glycolysis (Warburg effect) evidenced by increased trapping of
[18F]deoxyglucose (FdG) in patients imaged by positron emission tomography (PET). [18F]deoxyglucose uptake cor-
relates with glucose transporter (GLUT-1) expression, which can be regulated by hypoxia-inducible factor 1 alpha
(HIF-1α). We have previously reported in established breast lines that HIF-1α levels in the presence of oxygen leads
to the Warburg effect. However, glycolysis and GLUT-1 can also be induced independent of HIF-1α by other fac-
tors, such as c-Myc and phosphorylated Akt (pAkt). This study investigates HIF-1α, c-Myc, pAkt, and aerobic gly-
colysis in low-passage breast cancer cells under the assumption that these represent the in vivo condition better
than established lines. Similar to in vivo FdG-PET or primary breast cancers, rates of glycolysis were diverse, being
higher in cells expressing both c-Myc and HIF-1α and lower in cell lines low or negative in both transcription fac-
tors. No correlations were observed between glycolytic rates and pAkt levels. Two of 12 cell lines formed xenografts
inmice. Both were positive for HIF-1α and phosphorylated c-Myc, and only onewas positive for pAkt. Glycolysis was
affected by pharmacological regulation of c-Myc and HIF-1α. These findings suggest that c-Myc and/or HIF-1α ac-
tivities are both involved in the regulation of glycolysis in breast cancers.
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Introduction
Breast cancer is the most commonly diagnosed cancer among women
in the United States [1]. Thus, accurate methods for staging and di-
agnosis would have significant clinical benefit. Whole-body noninva-
sive imaging of [18F]deoxyglucose uptake using positron emission
tomography (FdG-PET) is considered to be the most reliable tech-
nique for the evaluation and prognosis of breast cancer [2–6]. FdG-
PET has been shown to accurately detect and differentiate malignant
from normal tissues at sensitivities of greater than 90% in breast and
other cancers [7–10]. Positron emission tomography imaging in
breast cancer is especially precise in the detection of nodal or distant
metastases [11–19]. However, the role of FdG-PET in the detection
and diagnosis of primary breast cancer is not well established due to
the limitations in detecting small-sized tumors with differentiated
histologic types [14,18,20–22] and heterogeneous FdG uptake pro-
files [2,7,18,20–27].
Abbreviations: LPR, lactate production rate; GUR, glucose uptake rate; HIF-1α, hypoxia-
inducible factor 1 alpha; SCID, severe combined immunodeficient; FdG, [18F]deoxy-
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A hallmark of malignant cancers is elevated uptake of glucose even
under normal oxygen conditions, known as “aerobic glycolysis” or
the Warburg effect [28]. Thus, the activity of glycolysis is elevated
independent of oxygen and is thus distinguished from the Pasteur
effect, which describes the elevation of glycolysis in response to hyp-
oxia. For reasons not fully understood, cells with a Warburg effect
continue to catabolize glucose at a high rate, even when mitochon-
drial oxidative pathways are available [29].
FdG-PET imaging does not differentiate between hypoxic (Pasteur
effect) and aerobic (Warburg effect) glycolysis, but studies using com-
bined 18-FdG and 18-F-misonidazole imaging have demonstrated
that FdG avidity and hypoxia are not highly correlated in vivo
[30,31]. Elevated aerobic glycolysis is a negative prognostic indicator
and may endow tumors with invasive potential and resistance to ra-
diation and chemotherapies [32,33]. FdG-PET imaging is used as a
therapy response biomarker [34,35], and thus, increased knowledge
regarding the regulation of deoxyglucose uptake is needed.
We have proposed that the aerobic glycolytic phenotype is estab-
lished in premalignant lesions (e.g., ductal carcinoma in situ, DCIS),
which grow toward ductal lumens where oxygen levels become limit-
ing. In DCIS, the intervening basement membrane serves as a physical
barrier preventing angiogenesis from relieving hypoxic stress, leading
to cyclic and intermittent hypoxia in periluminal cells [36–39]. This
microenvironmental stress promotes the selection of cells that exhibit a
phenotype with constitutive up-regulation of glycolysis [32,40]. Ex-
plicit in our models is the concept that, because selection is based
on phenotype and not genotype, multiple molecular mechanisms
may be observed that would impact a common phenotype (e.g., aer-
obic glycolysis) [41]. One knownmechanism is the stabilization of the
hypoxia-inducible factor 1 alpha (HIF-1α), which will up-regulate
genes necessary for maintaining tumor survival under stress, including
angiogenic factors and glycolytic enzymes [42–44]. We have further
proposed that, in metastases, the glycolytic phenotype persists due
to increased production of glucose-derived acid, which potentiates in-
vasiveness of cells into the extracellular matrix of the host tissue [32].
The molecular events leading to a glycolytic phenotype in breast
cancer are not well known [45]. Oncogenic factors including c-Myc
[46–48], Akt [49], and HIF-1α [50–54] have been implicated in
regulating aerobic glycolysis. These factors share a common preva-
lence in many types of cancers, are typically associated with cellular
response to stress, and demonstrate pleiotropic properties, including
the capacity to induce transcription of glycolytic genes. Therefore,
it is reasonable to hypothesize that evolving cells constitutively up-
regulate one or more of these factors to establish the Warburg effect
during carcinogenesis. Notable cross talk exists between these sys-
tems, viz, phosphorylated Akt (pAkt) can stimulate HIF-1α and
HIF-1α can inhibit the transactivation activity of c-Myc [55].
We have previously shown that HIF-1α was responsible for the
Warburg effect in established breast and renal cancer cell lines [52].
In the current work, we extend these analyses to a panel of low-passage
breast cancer lines, with the assumption that these primary cells are
more closely related to cells in vivo, compared to more established cell
lines. This investigation cross-correlated the glucose uptake (GURs)
and lactate production rates (LPRs) and the expression of glucose
transporter, GLUT-1, with the expression of activated pAkt, c-Myc,
and HIF-1α levels by immunoblot analysis and enzyme-linked immu-
nosorbent assay (ELISA). The primary lines were characterized under
atmospheric (160 mmHg) oxygen. Notably, a wide range of glycolytic
activities was observed across the cell lines, consistent with the variable
levels of FdG uptake observed in patients. No correlations between
pAkt and glucose consumption or LPRs were observed, whereas 10
of 12 cell lines showed significant correlations between glycolytic
rates and phosphorylated c-Myc and HIF-1α levels, which may be
interdependent. We investigated this further by treating cultured
tumor cells with 2-O-tetradecanoylphorbol-13-acetate (TPA) to stim-
ulate c-myc transactivation. Treatment up-regulated both phosphory-
lated c-Myc and nuclear HIF-1α expression and was accompanied
by an increase in glycolysis. In addition, inhibition of HIF-1α ac-
tivity with S -2-amino-3-[4′-N ,N ,-bis(2-chloroethyl)amino]phenyl
propionic acid N -oxide dihydrochloride (PX-478) [56] caused a dose-
dependent decrease in GURs. Thus, these data support the hypothesis
that either HIF-1α or c-Myc can function to induce the Warburg ef-
fect in breast cancers.
Materials and Methods
Cells and Reagents
Cell lines were obtained from the Arizona Cancer Center tumor
cell repository (Table 1). Tissue sources include surgically removed pri-
mary cancers, mostly pleural fluid efflusates and lymph node metas-
tases, and one isolated from ascites. Tumors were placed in a sterile
Petri dish and covered with M15 medium. M15 medium is composed
of Leibovitz’s L-15 medium containing glutamine, transferrin hydro-
cortisone, insulin, catalase, 2-mercaptoethanol, 10 mg/ml penicillin/
streptomycin (Sigma, St. Louis, MO), and 5% FBS. Necrotic tissue,
adherent connective tissue, fat, and blood clots were removed from
the tumor, and the remaining tumor tissue was transferred to a fresh
Petri dish containing medium. Tumor tissue was minced into 1- to
2-cm sections using a sterile, a #10 scalpel. Tumor samples were trans-
ferred to a conical tube, and medium was added. The supernatant
containing single cells and small-cell clusters was collected and placed
into a new conical tube. The remaining pellet was resuspended in
medium and centrifuged at 1000 rpm for 5 minutes. The supernatant
was discarded, and the pellet was resuspended in a collagenase solu-
tion (250 mg/100 ml). Tumor samples were incubated from 2 hours
to overnight at 37°C, checking hourly for loosened clusters with
individual rounded cells. After incubation, medium was added to
the top of the tube and centrifuged at 1000 rpm for 5 minutes. The
supernatant was removed, and the pellet was resuspended in fresh
medium. The supernatant containing single cells and small-cell clus-
ters was removed and placed into a new conical tube. Samples were
incubated with disaggregating enzymes if large tumor sections existed.
Tumor cells were qualitatively observed by optical microscopy. Debris
and red blood cells were removed using BSA debris removal technique
[57]. Tumor cells were seeded in tissue flasks and grown in a 37°C
incubator at 5% CO2.
Cells were maintained with weekly feedings involving the replace-
ment of spent medium with new nutrient-rich growth medium. Cell
lines growing in log phase (80% confluent) were subcultured in new
flasks in lesser numbers to induce active growth phase. The remain-
ing cells were kept frozen in liquid nitrogen. All cells have been cul-
tured under 10 passages. Established cell lines, MDA-mb-231 and
MDA-mb-435, were obtained from the American Type Culture
Collection (Rockville, MD) and maintained in Dulbecco’s modified
Eagle’s medium/F-12 supplemented with 10% FBS.
For tumor growth, 107 cells were suspended in 0.1 ml of Matrigel
and were injected bilaterally into mammary fat pads of 6-week-old
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female severe combined immunodeficient (SCID) mice at the Arizona
Cancer Center Experimental Mouse Shared Service. Tumor forma-
tion was monitored and measured electronically on a weekly basis.
Glucose Uptake
Glucose-trapping experiments were carried out as previously de-
scribed [52]. Briefly, cells growing in log phase were plated in 24-well
plates and allowed to attach. Cultures were washed in glucose-free
RPMI medium and treated with 4 μCi of [3H]-2-deoxy-D-glucose
in 5.56 mM D-(+)-glucose–supplemented medium for a 1-hour in-
cubation period. Control experiments showed that [3H]-2-deoxy-D-
glucose uptake was linear over this period. Supernatant was sampled
for liquid scintillation counting using a liquid scintillation counter
(5000TD; Beckman Coulter, Inc., Brea, CA). Cells were washed
and lysed with 0.1 N NaOH for 1 minute to generate extract sam-
ples for liquid scintillation counting. The remaining lysate was neu-
tralized with 0.1 N HCl and assayed for protein concentration using
Bradford reagent (Pierce, Rockford, IL). Glucose uptake rates were
calculated as nmol/min per milligram protein.
Lactate Production Assay
Cells growing in 96-well plates were washed three times with glucose-
free RPMI and treated with 10 mM D-(+)-glucose–supplemented,
serum-free RPMI for 1 hour incubation at 37°C in a humidified 5%
CO2 atmosphere. Lactate levels were quantified using an enzymatically
coupled lactic acid detection reagent (Sigma). Protein concentrations
were obtained andmeasured as described previously. Lactate production
rates were expressed as nmol/min per milligram protein.
Real-Time Quantitative Polymerase Chain Reaction
Total RNAwas isolated from cell lines with a GenEluteMammalian
Total RNA Miniprep Kit (Sigma) according to the manufacturer’s
instructions, followed by DNase treatment. Nucleic acid purity and
concentration (OD260/280) were measured on a μQuant universal mi-
croplate spectrophotometer (Bio-Tek Instruments, Inc., Winooski,
VT). Reactions were carried out on a SmartCycler (Cephid, Foster
City, CA) using a SYBRGreen reverse transcription–polymerase chain
reaction kit (Qiagen, Valencia, CA). Primers amplifying the human
gene products were as follows: GLUT-1 (forward –TCAATGCTGAT-
GATGAAC CTGCT, reverse – GGTGACACTTCACCCAC A
TACA); and β-actin (forward – CCGCATCGTCACCAACTG, re-
verse – GGCACACGCAGC TCATTG) (Invitrogen, Carlsbad, CA).
Data were normalized with the housekeeping gene, β-actin, as an in-
ternal control using the following formula: Relative gene expression =
2([β-actin C t] − [target gene C t]) [58].
Immunoblot Analysis and Immunohistochemistry
Cell extracts were processed with NE-PER Nuclear and Cytoplas-
mic Extraction Reagents (Pierce). Whole-cell lysates were prepared
for measuring membrane-bound GLUT-1 using a cell-lysing reagent
(Promega, Madison, WI). Extracts at equal concentrations (40 μg)
were separated electrophoretically on an 11% polyacrylamide gel and
transferred to Polyscreen PDVF blotting membrane (Perkin Elmer,
Boston, MA). Immunoblot analysis techniques were carried out ac-
cording to a protocol provided by Cell Signaling Technology (http://
www.cellsignal.com/index.asp). Blots were probed overnight at 4°C
with primary antibodies against human HIF-1α (1:250; Transduc-
tion Laboratories, Lexington, KY), phosphorylated c-MycThr58/Ser62
(1:1000), total c-Myc (1:1000; Cell Signaling,Danvers,MA), pAktSer473
(1:1000), total Akt (1:1000; Cell Signaling Technology, Beverly, MA),
HIF-2α (1:100, catalogue no. GTX28365; GeneTex, San Antonio,
TX), GLUT-1 (1:100), actin (1:400), and nuclear lamin (1:200; Santa
Cruz Biotechnology, Santa Cruz, CA). Membranes were counter-
probed with HRP-conjugated antimouse, -goat, or -rabbit polyclonal
IgG (1:10,000; Santa Cruz Biotechnology) secondary antibodies for
1 hour at room temperature. Blots were incubated in chemilumines-
cent substrate (Amersham Pharmacia, Uppsala, Sweden) for 1 minute
and imaged using a VersArray 1300B cooled charge-coupled device
camera (Roper Scientific, Duluth, GA) or exposed on BioMax film
(Kodak, Rochester, NY). For presentation purposes, the qualitative
images used in Figure 2 were selected from multiple blots carried
out in separate experiments as representative results. Raw data are
available in Figure W1.
Table 1. Low-Passage Breast Cancer Cell Lines from Arizona Cancer Center, Indicating Pathodiagnosis, Site of Collection, Age of Patient at Collection, Positive and Negative Markers, and Prior
Treatments Before Collection.
Arizona Cancer Center Cell Culture Core Facility
Established Breast Cell Line List
ACC# Pathology Site Age (years) Positive Markers Negative Markers Treatment
732 Adenocarcinoma Pleural fluid 35 neu, PR ER; EGFR VAC
812 Infiltrating ductal CA Left breast (primary) 43 neu ER, PR, EGFR VAC then CMF
893 Infiltrating ductal CA Right breast (primary) 57 neu, MAK-6 ER, PR, EGFR None
1179 Adenocarcinoma Pleural fluid 62 neu ER, PR, EGFR A, C, M, T
2087 Adenocarcinoma Left pleural fluid 53 EGFR, ka4, MAK-6, 10.11 ER, PR, neu; vim CMFVP, T
2150 Stage IIIB carcinoma Right pleural fluid 47 neu, MAK-6 ER, PR, EGFR, ras FAC, T, mito, velban
2648 Infiltrating ductal + lobular CA Right pleural fluid 58 ER, PR, ka4, 10.11 neu, EGFR, vim A, V, CMF/TP, velban, suramin/thiotepa
2715 Infiltrating ductal CA Left pleural fluid 66 ka4, 10.11, MAK-6 ER, PR, EGFR, neu, vim T, Megace, CMF, A
2925 Infiltrating ductal + lobular CA Ascites 46 ER, PR, EGFR, neu CMF, FAC, T, Mx, V
3133 Poorly differentiated adenocarcinoma +
lobular CA
Pleural fluid 63 neu ER, PR, EGFR Surgery only
3171 Poorly differentiated metastatic carcinoma Lymph node 42 S-100 ER, PR, EGFR, neu, CEA, vim CAF
3199 Infiltrating ductal CA Axillary nodes 58 EGFR ER, PR, neu CAF, T, Mx, V
CEA indicates carcinoembryonic antigen; EGFR, epidermal growth factor receptor; ER/PR, estrogen and progesterone receptor status of cell line; ka4, 10.11, and MAK-6 recognize cytokeratins 8, 14, 15,
16, 18, and 19; neu, HER-2/neu oncogene; ras, oncogene product; S-100, serum protein elevated in the blood of patients with metastatic disease; vim, vimentin.
Treatments: A indicates adriamycin; C , cytoxan; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil combination therapy; CMF/TP, CMF with thymidine phosphorylase; F, 5-fluorouracil;
M , methotrexate; Megace, megesterol acetate; mito, mitomycin C; Mx, mitoxantrone; suramin/thiotepa, cancer drugs; T, tamoxifen; V, vinblastine; velban, vinblastine.
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For immunohistochemistry, the tumor sections were placed imme-
diately in ice-cold 1% formalin containing a phosphatase-inhibiting
reagent (VentanaMedical Systems, Tucson, AZ), dehydrated, paraffin-
embedded, and stained by the Tissue Acquisition and Cellular Macro-
molecular Analysis Shares Service of the Arizona Cancer Center. A
series of sequential 7-μm sections were cut from the center of fixed
tumors, stained with eosin, and counterstained for antigens (pAkt and
total Akt). Antibodies were be coupled to HRP and stained with di-
aminobenzidine (DAB). Images were digitized in RGB using a 1×
objective on an inverted bright field microscope (Diaphot; Nikon,
Melville, NY) coupled to a 12-Megapixel charge-coupled device
(Photometrics, Tucson, AZ) with an 8-mm field of view, yielding a
nominal resolution of 2.2 × 2.2 μm2.
Enzyme-Linked Immunosorbent Assay
Semiquantitative levels of nuclear HIF-1α transactivation activ-
ity were measured by TransBinding HIF-1α Assay Kit (Panomics,
Redwood City, CA) according to the manufacturer’s instructions. C-
Myc activity was measured similarly by TransAM Transcription Factor
Assay Kit (Active Motif, Carlsbad, CA). Values were expressed as ab-
sorbance measurements (450 nm) normalized to protein concentra-
tions after subtraction of negative control background absorbance.
Transcription Factor Induction and Inhibition
At 24 hours before treatment with TPA, cells seeded in 24-well
assay plates were grown in serum-free RPMI. The medium was re-
moved and replaced with RPMI containing 10% FBS and 15 nM
TPA. Cells were allowed to incubate in normoxia for 2 hours with
untreated controls. Cells were subsequently tested for supernatant
lactate levels and harvested for protein extraction and immunoblot
analysis experiments.
Anti–HIF-1α PX-478 was kindly donated by Garth Powis from
the Arizona Cancer Center, Tucson, AZ. Toxicity thresholds were
measured in both cell lines by crystal violet analysis (unpublished data).
MDA-mb-231 cells were grown to 80% confluency then treated
with nontoxic doses of PX-478 resuspended in growth medium.
Cells were grown 24 hours under hypoxia (O2 = 2%) at 37°C. Cul-
tures were tested for GUR and harvested for protein extraction and
immunoblot analysis experiments.
Statistics
All statistical calculations were determined using the analysis fea-
ture in GraphPad Prism version 4.03 for Windows (GraphPad Soft-
ware, San Diego CA; http://www.graphpad.com). Linear regression
was used to test whether the slope of the line deviated from the zero
slope in data sets. Unpaired, two-tailed t tests were used to determine
whether means were significantly different between the two data sets.
Data set correlations were considered significant when P < .05.
Results
Breast Tumor Lines Exhibit Variable Rates of Glucose Uptake
and Lactate Production under Normoxic Conditions
FdG-PET is generally equivocal in diagnosing and staging breast
cancers because of its high variability [3,7,18,20–27]. To investigate
the molecular basis of such variation, the glycolytic phenotypes of
low-passage breast tumor lines were examined in vitro with glucose
uptake, lactate production, and GLUT-1 mRNA transcript expres-
sion. Established metastatic breast cancer lines MDA-mb-231 and
MDA-mb-435 were included in these studies as reference points
for other published studies. The results from these experiments are
summarized in Table 2.
Specific rates of glucose trapping were determined using [3H]-2-
deoxy-D-glucose (2dG) in RPMI medium. The mean uptake rate
was 2.3 ± 0.4 nmol/min per milligram protein with a range of 0.6
to 5.6 nmol/min per milligram protein. Four of the 12 cell lines
(ACC-3199, ACC-893, ACC-2638, and ACC-2087) exhibited up-
take rates comparable to both MDA-mb-231 and MDA-mb-435,
whereas four other cell lines (ACC-732, ACC-1179, ACC-3133,
and ACC-2925) had significantly lower rates than MDA-mb-231
(P < .05). Cell lines ACC-2715 and ACC-3171 exhibited uptake
rates significantly lower than MDA-mb-231 and MDA-mb-435,
whereas cell lines ACC-812 and ACC-2150 consumed glucose at a
significantly higher rate than the established lines (P < .05).
Although 2dG trapping is an effective kinetic evaluation of facil-
itative glucose transporter and hexokinase activities, it does not mea-
sure glucose metabolism. To verify that glucose uptake resulted in
metabolism, LPRs were also determined under the same conditions.
The mean LPR was 9.3 ± 1.3 nmol/min per milligram protein, and
the range of values was 0.6 to 16.8 nmol/min per milligram pro-
tein. Figure 1A shows that the relationship between LPR and GUR
was significantly nonzero (P = .0017), with a linear correlation coeffi-
cient (r2) of 0.45. There were three outliers beyond 95% confidence
intervals, namely, ACC-893, ACC-3171, and ACC-3199, which pro-
duced lactate at high rates (13.7, 10.9, and 10.1 nmol/min per mil-
ligram), yet consumed glucose at relatively low rates (2.0, 1.1, and
2.2 nmol/min per milligram), respectively. When these were excluded
from analysis, the linear correlation coefficient increased to 0.85, sug-
gesting that, for the remaining cells, the lactate was derived from glu-
cose through glycolysis.
These results show that there is a wide range of glycolytic pheno-
types among the 12 primary breast tumor lines. Cell line ACC-2715
had the lowest GUR and LPR, whereas ACC-812 and ACC-2150
had highest glycolytic activity (Table 2). Among the other cells,
the dynamic ranges were approximately fourfold for both GUR
and LPR. A dynamic range of 4.3-fold for glucose trapping is con-
sistent with specific uptake values observed by FdG-PET in clinical
studies with breast cancer patients [25].
Table 2. Glycolytic Phenotype of Breast Tumor Lines.














ACC-732 4.9 (0.7) 1.9 (0.39) 12.7 0.7
ACC-812 16.8 (1.1) 5.6 (1.0) 21.8 0.0
ACC-893 13.7 (1.7) 2.0 (0.46) 17.6 2.5
ACC-1179 7.6 (1.2) 1.4 (0.30) 27.5 4.1
ACC-2087 9.2 (1.6) 2.2 (0.28) 18.3 2.5
ACC-2150 10.2 (0.8) 4.7 (0.44) 5.4 1.0
ACC-2648 5.8 (1.0) 2.3 (0.55) 12.2 2.3
ACC-2715 0.6 (0.02) 0.6 (0.17) 8.8 2.6
ACC-2925 3.9 (0.6) 1.5 (0.26) 7.4 0.5
ACC-3133 6.0 (0.6) 1.8 (0.33) 3.3 21.4
ACC-3171 10.9 (1.9) 1.1 (0.29) 14.9 1.4
ACC-3199 10.1 (1.4) 2.2 (0.08) 12.8 0.0
MDA-mb-435 11.8 (0.3) 1.7 (0.06) 25.0 110.0
MDA-mb-231 18.9 (1.8) 3.1 (0.33) 4.1 120.9
Mean (SEM) of LPRs, GURs, GLUT-1 mRNA, and GLUT-3 mRNA levels (n ≥ 3).
748 Aerobic Glycolysis in Breast Cancer Robey et al. Neoplasia Vol. 10, No. 8, 2008
GLUT-1 mRNA Expression in Low-Passage Breast
Tumor Lines
Glucose uptake is regulated by glucose transporters expressed on the
cell surface and it represents a rate-limiting step in glycolysis. The rate
of uptake is controlled primarily by transporter levels, and this can
be reflected by transporter mRNA expression [52,59]. Consequently,
glucose transporter mRNA expression levels were determined and
quantitatively compared to the kinetic studies. Both GLUT-1 and
GLUT-3 expressions were investigated, because these glucose trans-
porters have been associated with uptake of glucose in cancers and
exhibit high affinities for both glucose and FdG [60,61]. GLUT-3
levels were low in all primary cell lines, except ACC-3133 that ex-
pressed levels exceeding that of MDA-mb-231. GLUT-3 mRNA
levels showed a negative, yet insignificant, correlation to both GUR
Figure 1. Corelationships between glycolytic markers in breast tumor lines. Linear correlations in the 12 primary breast tumor lines
between LPRs and GURs (P = .0173; A), GURs and GLUT-1 mRNA levels (B), GUR and GLUT-3 mRNA levels (C), LPRs and GLUT-1
mRNA levels (D), and lactate production and GLUT-3 mRNA (E).
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and LPR (Figure 1, C and E ). GLUT-1 is often overexpressed in ma-
lignant cancers and is a negative prognostic marker in breast cancer
[25,62–64]. GLUT-1 mRNA levels ranged approximately eightfold,
from 3.3 to 27.5 × 10−5 copies relative to actin mRNA. GLUT-1 levels
were more linear to LPR (Figure 1D) than to GUR (Figure 1B), but
this analysis was not statistically significant.
Evaluation of Nuclear HIF-1α and Phosphorylated c-Myc
with Aerobic Glycolysis
Hypoxia-inducible factor 1 alpha is a subcomponent of the heterodi-
meric HIF-1 transcription factor. It is constitutively produced in the cyto-
plasmbut rapidly degraded by an ubiquitin-mediated systemwhen oxygen
is present. If oxygen tension becomes critically low, HIF-1α accumulates,
Figure 2. Nuclear expression of phosphorylated c-Myc and HIF-1α. Immunoblot analysis of c-MycThr58/Ser62, total c-Myc, HIF-1α, and lamin
loading from nuclear extracts of ACC-cell lines (A). These data were correlated to activities, as measured by ELISA (B, D) and LPR (C, E).
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is phosphorylated, and is translocated to the nucleus where it combines
with the HIF-1β/ARNT DNA binding component [43,44,65–67].
Hypoxia-inducible factor 1 coordinately induces the expression of glyco-
lytic enzymes, including the GLUT-1 glucose transporter [68–70].
Nuclear HIF-1α expression under normoxic conditions was exam-
ined in each of the breast tumor lines byWestern immunoblot analysis
(Figure 2A). The HIF-1α signal was observed in 5 of 12 primary cell
lines. Band intensities were scored from 1 to 4, with 1 being weak
staining (ACC-812 cells) and 4 representing high levels (ACC-3171
and ACC-3199 cells). ACC-2087 and ACC-893 cells had interme-
diate HIF levels (score 2). Both of the stable cell lines (MDA-mb-
231 and MDA-mb-435) exhibited strong HIF-1α staining. Nuclear
HIF-1α levels were also examined by ELISA. Although we observed
a wide range of variability in the ELISA test, we were still able to as-
certain a significant association with theWestern blot data, confirming
the viability of the Western blot analysis results (Figure 2B). Cell lines
that ranked as a 4 in the Western blot analysis had significantly higher
ELISA values compared to cell lines that scored 0, 1, and 2 (P = .001).
The HIF-1α status of the primary cell lines was also compared to
LPRs, as shown in Figure 2C . The two primary cell lines with the
highest average LPR (ACC-812 and ACC-893) were only weakly
positive for HIF-1α. It may be noteworthy that these were the only
two cell lines in this panel that were isolated from primary tumors
and not metastases. It is possible that HIF-2α is responsible for gly-
colytic regulation under normoxia in these cell lines [71]. Our inves-
tigations discovered that HIF-2α was expressed in cell line ACC-812
but not in ACC-893 (Figure 3). All of the cell lines positive for HIF-
1α staining exhibited higher LPRs compared to cells that did not
express measurable levels of HIF-1α (P = .038). Somewhat surpris-
ingly, there was no correlation between measurable HIF-1α levels
and GURs. The HIF-1α–positive and –negative cells had mean ±
SEM GURs of 2.62 ± 0.77 and 2.02 ± 0.49, respectively (P =
.26; α = 0.05, one-sided with equal variance).
The c-Myc transcription factor has been implicated in regulating
glycolysis in tumor cells through transactivation of lactate dehydro-
genase A [48], up-regulation of GLUT-1 genes [47], and coordinate
induction of all glycolytic enzymes [46]. C-Myc is regulated by phos-
phorylation at Thr58 and Ser62 residues, which facilitates binding to
DNA and initiation of transcription [72]. Nuclear extracts from cell
lines grown under normoxia were probed with antibodies against
phosphorylated c-MycThr58/Ser62 along with total c-Myc levels
(Figure 2A). Total c-Myc was detected in all cell lines except for
ACC-2715. Phosphorylated c-Myc was observed in all cells except
ACC-3133 and ACC-2715, with strongest intensities in ACC-
3171, ACC-3199, and ACC-2087 cells. The stable lines MDA-
mb-231 and MDA-mb-435 also stained strongly for phosphorylated
c-Myc. Cells lines from the Western blots were scored in the same
manner as the HIF-1α Western blots and compared to the results
from an ELISA measuring c-Myc binding to consensus sequence
DNA. As shown in Figure 2D, the findings from these analyses were
similar to the HIF-1α analysis. The cell lines that ranked as a 4 in the
Western blot analysis had significantly higher ELISA absorbance val-
ues than cell lines ranked as a 0, 1, 2, and 3 (P = .0018).
As with the HIF-1α analysis, phosphorylated c-Myc status was com-
pared to LPRs (Figure 2E). Here, we also observed a strong association
between glycolytic phenotype and phosphorylated c-Myc status. How-
ever, as previously mentioned, cell lines ACC-812 and ACC-893 were
clear outliers, with unusually high LPRs. Cell lines with the highest
phosphorylated c-Myc signals (ACC-2087, ACC-3171, and ACC-
3199) had significantly higher LPR compared to cell lines with weaker
or negatively phosphorylated c-Myc signals (P = .038). Notably, in cell
lines ACC-812 and ACC-893, it is clear that neither HIF nor Myc
was involved in regulating aerobic glycolysis in these cell lines. For
the other cells, these findings suggest a role for both HIF-1 and
c-Myc activation in maintaining the Warburg effect in breast cancer.
Akt Does Not Correlate with Glycolysis
The serine/threonine kinase, Akt is activated by phospholipid
binding and activation loop phosphorylation at Thr308 by PDK1
and by phosphorylation within the carboxy-terminus at Ser473
[73]. Akt has been shown to regulate glycolysis at several steps
through posttranscriptional mechanisms. Akt localizes GLUT-1 to
the cell surface and the maintenance of hexokinase function activity
[74]. This activity has been shown to regulate aerobic glycolysis in
tumor cells. For example, murine pro–B-cell lymphoid cells trans-
formed with inducible Akt demonstrate up-regulated glucose uptake
in vivo, and Akt-transformed human glioblastoma cells metabolize
glucose in correlation with Akt activity in vitro [49]. Whole-cell ex-
tracts from breast tumor lines were analyzed for the expression of
activated Ser473 pAkt [73] (Figure 4A) by the same methods used
previously for the c-Myc analysis. Total Akt was observed in all breast
tumor lines. Phosphorylated Akt levels were observed in all cell lines
except ACC-3199, ACC-2648, and ACC-732. Cell lines ACC-
2925, ACC-2150, and ACC-893 expressed the highest intensities
of AktSer473. The ratio of mean band intensities between pAkt and
total Akt was determined using the measure function in the ImageJ
downloadable application [75].
Expression of pAkt as a ratio to total Akt was compared to LPRs in
each cell line (Figure 4B). A linear regression analysis determined that
there was no significant deviation from zero in this comparison (P =
.87). We conclude that transactivation of Akt is not necessary to reg-
ulate aerobic glycolysis in breast cancer cells and its activity—in par-
ticular reference to cell line ACC-2925—does not seem to enhance
cellular glycolysis under normoxic conditions.
Pharmacologic Manipulation of c-Myc and HIF-1α
ACC-3199 cells were cultured overnight in serum-free medium to
reduce activated c-Myc levels. Cultures were then treated with TPA, a
reagent that acutely activates c-Myc through kinase C–mediated phos-
phorylation [76]. 2-O-Tetradecanoylphorbol-13-acetate caused a
nearly twofold increase in lactate production after a 2-hour incuba-
tion (P = .004) along with a corresponding increase in c-MycThr58/Ser62
Figure 3. Nuclear expression of HIF-2α. Immunoblot analysis of HIF-
2α and lamin loading from nuclear extracts of ACC-812 and ACC-893.
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levels (Figure 5). The blots were stripped with 0.2 M NaOH and
gentle shaking for 10 minutes and were reprobed for HIF-1α. The
process was repeated for nuclear lamin A/C loading control. Notably,
HIF-1α expression was present under both conditions, and levels were
relatively unchanged by TPA treatment (Figure 5).
These results suggest two possible mechanisms of glycolytic up-
regulation induced by TPA treatment. Activity of phospho–c-Myc
induced by TPA may have directly increased glycolytic activity in
ACC-3199 cells. Alternatively, a regulatory dynamic relationship be-
tween c-Myc and HIF-1 may exist.
To further test this relationship, inhibition of HIF-1α was accom-
plished with PX-478, a reagent that targets HIF-1α, possibly through
mRNA stability [56]. MDA-mb-231 cells were cultured under hyp-
oxic conditions (O2 = 2%) for 24 hours to maximally up-regulate
HIF-1α expression and treated with 20 and 40 mg/ml of PX-478.
Both GUR and HIF-1α coordinately and significantly decreased in
a dose-dependent manner (Figure 6).
Tumor Formation
As a final test to characterize the phenotypes exhibited by this panel
of cell lines, each cell line was inoculated bilaterally into mammary fat
pads of two female SCID mice (four inocula per cell line) to test their
ability to grow as tumors. Of 12 cell lines, only 4 formed tumors:
ACC-3199, ACC-3171, ACC-2150, and ACC-893. This observation
is consistent with other reports discussing investigations working
with primary breast cancer cell lines in animals [77]. To establish a sta-
ble cell line without genetic drift as seen typically in low-passage cell
lines, the tumors that grew were reimplanted twice into more SCID
mice for a total of three passages. ACC-2150 and ACC-893 failed to
grow after reimplantation. Hence, only ACC-3199 and ACC-3171
were able to grow reproducibly as tumors in SCIDmice. Notably, their
pAkt status did not change during growth: i.e. ACC-3199 remained
pAkt-negative, whereas ACC-3171 was strongly pAkt-positive (Fig-
ure 7). Both of these cell lines were positive for phospho–c-Myc and
HIF-1α, and these molecular phenotypes also did not change during
in vivo selection (data not shown).
Discussion
Whereas FdG uptake is uniformly high in aggressive and meta-
static cancers, its use as a pathodiagnostic agent in breast cancer is
limited to its high variability. The purpose of these studies was to
Figure 4. Nuclear expression of pAkt and total Akt. (A) Immunoblot of Ser473 pAkt, total Akt, and GAPDH control from nuclear extracts of
ACC breast tumor lines. (B) Correlation of pAkt mean band intensities normalized to total Akt expression and lactate production, P = .87.
Figure 5. Expression of phosphorylated c-Myc, HIF-1α, and lactate
production in TPA-treated breast tumor cell line. Increase of c-Myc
expression and lactate production when ACC-3199 cells are treated
with 15 mM TPA for 2 hours.
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investigate the molecular mechanisms underlying FdG uptake vari-
ability. In this study, we examined glycolytic phenotypes and the pos-
sible relationships between aerobic glycolysis and expression of
oncogenic factors associated with malignancy. This investigation fo-
cused on 12 low-passage breast tumor lines and included two estab-
lished metastatic breast tumor lines for comparison. Both glucose
uptake and lactic acid production were variable, but highly correlated,
among the individual cell lines. This is consistent with the observed
variability of FdG uptake by PET scanning in breast cancer pa-
tients [2,7,18, 20–27]. Breast carcinomas with higher rates of FdG
uptake have the poorest prognosis [2–5].
Elevated FdG uptake may be associated with the Warburg effect.
The relationship between the Warburg effect and malignancy sug-
gests a possible selective advantage to cancer cells, but a proliferative
advantage is not apparent. Glycolysis is energetically less efficient
than oxidative phosphorylation and produces toxic byproducts. Se-
lection of the Warburg effect for purposes of energetic fitness is
not logical considering that aerobic glycolysis is an existing metabolic
function in all eukaryotic cells. It must be considered, therefore, that
aerobic glycolysis is not selected for production of ATP. A relatively
minor fraction (<30%) of a cancer cell’s aerobic ATP production is
derived from glycolysis according to mass balance analyses [78].
There are explanations, other than bioenergetics, which address this
observation. Glycolysis produces hydrogen ions, and increased acid-
ity offers a selective advantage to invading tumor cells. Alternatively,
Glucose metabolism may occur through the pentose phosphate path-
way, providing anabolic substrates such as ribose for nucleic acid syn-
thesis as well as reducing equivalents (NADPH) to combat reactive
oxygen species [79,80]. This material is discussed in greater detail in
a recent review by Gillies and Gatenby [81].
In most of the cell lines, GUR correlated to LPR, indicating that
either measurement would reflect rates of glucose metabolism for al-
most all cells. Outliers in this analysis were ACC-893, ACC-3171, and
ACC-3199, which all produced lactate at rates higher than would be
expected from their GURs. Interestingly, these three cell lines were also
tumorigenic in SCID mice. High rates of lactate production by these
cells may be due to additional lactate-producing pathways such as en-
hanced glutaminolysis [82], and this remains to be confirmed. The cell
line ACC-812 exhibited the highest rate of glycolysis by either mea-
surement yet had lower than expected levels of both HIF-1α and c-
Myc (Figure 2). These cells were isolated from primary tumor sites
compared to the others that were isolated from lymph nodes or pleural
effusions. ACC-812 cells were also not tumorigenic in SCID mice.
Glucose transporter levels are a common end point in cancer studies
due to high expression in tumormalignancy and its positive correlation
with FdG-PET studies [25,64]. In previous studies with established
breast tumor lines, others and we have noted that GLUT-1 mRNA
expression can reflect GLUT-1 protein expression [52,59], yet these
results can not be extrapolated to the current study. This could be
due to a combination of several factors. Although there is evidence sup-
porting a correlation between mRNA and protein expression [83],
there may be unknown posttranscriptional modifications or protein
half-lives that would not be reflective of the true level of active glucose
transporters when making comparisons to transcript levels. This phe-
nomenon has been observed in cultured cells with disrupted oxidative
phosphorylation [84]. This was noted in our own experiments as well.
For example, cell lines ACC-1179, ACC-893, and ACC-3199 ex-
pressed comparably higher levels of GLUT-1 message but exhibited
weak GLUT-1 protein expression (Figure W1). GLUT-3 could also
contribute to GUR, and it is highly expressed in the stable cell lines
MDA-mb-231 and MDA-mb-435. However, in the current panel,
there is no significant relationship between expression of this gene
and either GUR or LPR (Figure 1).
Both aerobic glycolysis and GLUT-1 levels may be stimulated by a
host of oncogenic factors, such as HIF-1α [50–54], c-Myc [47,48],
Figure 6. Effect of PX-478 onHIF-1α and glycolysis. Dose-dependent
decrease in glucose uptake in MDA-mb-231 cells (20 and 40 μg/ml)
after 24 hours of treatment with PX-478 under hypoxia (O2 = 2%).
*P = .01 compared to untreated controls.
Figure 7. Immunohistochemistry for pAkt in ACC-3171 and ACC-3199 tumors. Breast tumor cell lines grown in SCID mice and then
reimplanted into new SCID mice were stained for pAkt. ACC-3171 demonstrated a positive staining for pAkt, whereas ACC-3199 was
negative for pAkt.
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or Akt [49]. We noted that earlier reports have shown HIF-1α levels,
measured with histologic diagnosis, did not correlate well with increased
FdG uptake measured by PET in breast cancers [25]. Hence, we were
concerned that the relationship between HIF-1α and the Warburg
effect was particular to cell lines that were established in culture. To
examine this, we developed a series of low-passage breast cancer lines,
with the rationale that they would more adequately represent cells
from in vivo tumors. We observed that cell lines exhibiting the highest
relative rates of aerobic glycolysis were positive for nuclear HIF-1α.
Notably, cell lines with lowest glycolytic rates were negative for the
expression of nuclear HIF-1α. Clear exceptions to these observations
are cell lines ACC-812 and ACC-893, both of which were highly
glycolytic but expressed low or negative levels of normoxic HIF-1α.
Although it does not seem that HIF-1α is involved in glycolytic reg-
ulation of these two cell lines, it is possible that HIF-1 homologues
such as HIF-2αmay be up-regulated in these cells [71] and contribute
to glycolytic regulation under normoxia. We tested for the expression
of this factor in ACC-812 and ACC-893 and discovered that the ex-
pression of HIF-2α was indeed positive and comparable to a nuclear
extract from metastatic breast tumor line (MDA-mb-435) that had
been cultured under hypoxic conditions (O2 at 2% for 24 hours).
We did not observe any expression of HIF-2α in ACC-893 (Figure 3).
Another possibility for the Warburg effect in these cell lines—and
this remains to be tested—is the regulation by a cell cycle regulator
ubiquitin ligase with the F-box protein Grr1 (SCFGrr1), which has
been shown to target transcription factors involved in regulating
glycolysis [85].
It was previously reported that transactivation of c-Myc is depen-
dent on its phosphorylation at Thr58 and Ser62 [72]. This event is
somewhat complicated in that phosphorylation of c-Myc at Ser62
promotes stabilization and accumulation of c-Myc and conversely,
phosphorylation of c-Myc at Thr58 accelerates c-Myc ubiquitination
and proteolytic degradation [86]. Dephosphorylation of Ser62 is re-
quired, however, for degradation to occur [87]. We examined the ex-
pression of c-MycThr58/Ser62 and observed a general correspondence
with aerobic glycolysis in the primary breast tumor lines. These data
corresponded with the ELISA experiments that measured c-Myc
binding to an immobilized oligonucleotide containing the c-Myc
consensus binding site (5′-CACGTG-3′; Figure 2D), thus we inter-
pret c-MycThr58/Ser62 expression to indicate c-Myc activity. There was
a higher expression of c-MycThr58/Ser62 in glycolytic lines ACC-3199,
ACC-3171, and ACC-2087, which were comparable to the stable
cell lines MDA-mb-231 and MDA-mb-435. We also noted lower
or negative c-Myc activity in cells with lowest glycolytic rates. Similar
to HIF-1α, cell lines 812 and 893 expressed low levels of phosphor-
ylated c-Myc but had the highest LPRs, suggesting that other factors
are responsible for regulating glucose metabolism in these cell lines.
We also examined pAkt expression in this panel. Phosphorylated
Akt expression was examined along with total Akt levels relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a common
cytoplasmic protein loading control. GAPDH expression was robust
in all cell lines but variable. This may be due to the role of GAPDH
in glycolysis. Therefore, the levels of pAkt expression in cells were also
expressed as a ratio between pAkt and total Akt from the band inten-
sities in the Western blot (Figure 4A). Both pAkt/total Akt and pAkt/
GAPDH ratios were compared to lactate production and showed no
significant relationship.
At the outset of these studies, cross talk between c-Myc and HIF-1
had not previously been seen. We began to examine this in more de-
tail when it was reported in two systems by Semenza and Dang
[55,88]. To test the hypothesis that c-Myc and HIF-1α can regulate
the glycolytic phenotype in breast cancer cells, c-Myc was activated
with TPA. 2-O-Tetradecanoylphorbol-13-acetate induced both phos-
phorylated c-Myc along with a significant increase in lactate produc-
tion. Effects of TPA on c-Myc phosphorylation are consistent with
previous reports [76]. It should be noted that HIF-1α levels are also
reportedly affected by TPA [89,90]. One study [89] provided evi-
dence that phorbol-12-myristate-13-acetate induced HIF-1 through
mitogen-activated protein/extracellular signal–regulated kinase 1
(MEK-1) signaling. Transcription factor c-Myc can activate the
MEK-1 pathway, at least in rhabdomyosarcoma cells [91]. To test if
inhibition of these transcription factors would down-regulate glycoly-
sis, HIF-1α was inhibited with PX-478 [56], and this led to dose-
dependent decreases in both HIF-1α and glucose uptake. Hence,
we conclude that theWarburg effect in these cell lines is also associated
with elevated HIF-1α levels and that the effect is amplified by c-Myc.
Because this does not explain the lack of correlation observed in vivo,
we also conclude that in vivo FdG uptake can be driven by other path-
ways in addition to HIF-1α.
We have recently developed a model to explain why cancers have
high glycolysis [32]. This model predicts that expression of a glyco-
lytic phenotype is essential to cancer progression and predicts that
this can be achieved through multiple mechanisms that can be dif-
ferent even within specific types of cancers. The results of this study
are consistent with this prediction in that two transcription factors, c-
Myc and HIF-1, seem to be mutually associated with regulation of
aerobic glycolysis.
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Figure W1. GLUT-1 protein expression. Immunoblot analysis of GLUT-1 and actin from whole–tumor cell lysates.
